U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C26H31Cl2N3.3H3O4P
Molecular Weight 750.436
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of AMINOQUINOL TRIPHOSPHATE

SMILES

OP(O)(O)=O.OP(O)(O)=O.OP(O)(O)=O.CCN(CC)CCCC(C)NC1=CC(\C=C\C2=C(Cl)C=CC=C2)=NC3=CC(Cl)=CC=C13

InChI

InChIKey=NHNXMYYNFQHZMQ-XPGLNUPKSA-N
InChI=1S/C26H31Cl2N3.3H3O4P/c1-4-31(5-2)16-8-9-19(3)29-26-18-22(14-12-20-10-6-7-11-24(20)28)30-25-17-21(27)13-15-23(25)26;3*1-5(2,3)4/h6-7,10-15,17-19H,4-5,8-9,16H2,1-3H3,(H,29,30);3*(H3,1,2,3,4)/b14-12+;;;

HIDE SMILES / InChI

Molecular Formula C26H31Cl2N3
Molecular Weight 456.45
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 1
Optical Activity ( + / - )

Molecular Formula H3O4P
Molecular Weight 97.9952
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Aminoquinol (XIB4035) is a nonpeptidyl small molecule agonist for GFRalpha-1. XIB4035 concentration-dependently inhibited [(125)I]GDNF binding in Neuro-2A cells with an IC(50) of 10.4 uM. GDNF induced autophosphorylation of Ret protein, and promoted neurite outgrowth in Neuro-2A cells. XIB4035, like GDNF, induced Ret autophosphorylation in the Neuro-2A cells. Moreover, XIB4035 promoted neurite outgrowth in a concentration-dependent manner. These results show that XIB4035 may act as an agonist at GFRalpha-1 receptor complex, and mimic neurotrophic effects of GDNF in Neuro-2A cells. It has been shown that topical application of XIB4035 is an effective treatment for small-fiber neuropathy (SFN). Topical application of GFRα/RET receptor signaling modulators may be a unique therapy for SFN, and XIB4035 is a candidate therapeutic agent. Aminoquinol has been also used in the therapy of cutaneous leishmaniasis and lambliasis.

Approval Year

PubMed

PubMed

TitleDatePubMed
[ON THE EFFECTIVENESS OF TREATMENT OF LAMBLIASIS IN CHILDREN WITH AMINOQUINOL].
1965 Apr
[On the problem of the comparative effectiveness of aminoquinol and acriouine therapy in lambliasis].
1967 Feb
Crystallographic and spectroscopic studies of native, aminoquinol, and monovalent cation-bound forms of methylamine dehydrogenase from Methylobacterium extorquens AM1.
1998 Oct 2
Treating small fiber neuropathy by topical application of a small molecule modulator of ligand-induced GFRα/RET receptor signaling.
2014 Feb 11
Patents

Sample Use Guides

A cream containing XIB4035 (1.2 mM) was generated and applied directly to the hind paws of GFAP-DN-erbB4 and wild type mice twice daily for a period of 4 weeks starting at the time of weaning (P21).
Route of Administration: Topical
The binding of [125I]GDNF to the Neuro-2A cells was concentration-dependently inhibited by Aminoquinol (XIB4035). IC50 value of XIB4035 in displacing [125I]GDNF binding was 10.4 uM.
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:41:24 GMT 2023
Edited
by admin
on Sat Dec 16 09:41:24 GMT 2023
Record UNII
K0588F7XOC
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AMINOQUINOL TRIPHOSPHATE
Systematic Name English
1,4-PENTANEDIAMINE, N4-(7-CHLORO-2-(2-(2-CHLOROPHENYL)ETHENYL)-4-QUINOLINYL)-N1,N1-DIETHYL-, PHOSPHATE (1:3)
Systematic Name English
Code System Code Type Description
FDA UNII
K0588F7XOC
Created by admin on Sat Dec 16 09:41:24 GMT 2023 , Edited by admin on Sat Dec 16 09:41:24 GMT 2023
PRIMARY
PUBCHEM
6444420
Created by admin on Sat Dec 16 09:41:24 GMT 2023 , Edited by admin on Sat Dec 16 09:41:24 GMT 2023
PRIMARY
CAS
3653-53-0
Created by admin on Sat Dec 16 09:41:24 GMT 2023 , Edited by admin on Sat Dec 16 09:41:24 GMT 2023
PRIMARY
Related Record Type Details
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
Related Record Type Details
ACTIVE MOIETY